| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/10/2011 | US20110059928 Graduated estrogen contraceptive |
| 03/10/2011 | US20110059909 Methods for treating inflammatory disorders |
| 03/10/2011 | US20110059896 Use of furin convertase inhibitors in the treatment of fibrosis and scarring |
| 03/10/2011 | US20110059125 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 03/10/2011 | US20110059120 Glucan-based vaccines |
| 03/10/2011 | US20110059066 PAKs as Modifiers of the CHK Pathway and Methods of Use |
| 03/10/2011 | US20110059026 Pharmaceutical dosage form bearing pregnancy-friendly indicia |
| 03/10/2011 | US20110059015 Vaccine |
| 03/10/2011 | CA2809198A1 Combination medicament |
| 03/10/2011 | CA2773083A1 Immunity-inducing agent |
| 03/10/2011 | CA2772354A1 Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
| 03/09/2011 | EP2292632A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 03/09/2011 | EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 03/09/2011 | EP2292595A1 Potassium channel modulators |
| 03/09/2011 | EP2292269A2 Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| 03/09/2011 | EP2292268A1 Pharmaceutical composition for use in treatment of diabetes |
| 03/09/2011 | EP2292267A2 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 03/09/2011 | EP2292251A1 Combination therapy using anti-angiogenic agents and TNF-alpha |
| 03/09/2011 | EP2292244A2 Salt Solution for Colon Cleansing |
| 03/09/2011 | EP2292239A2 Remedies for diseases to be applied to eye |
| 03/09/2011 | EP2292237A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 03/09/2011 | EP2292236A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292232A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II |
| 03/09/2011 | EP2292220A2 Composition and methods for increasing insulin sensitivity |
| 03/09/2011 | EP2292210A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 03/09/2011 | EP2291197A1 Use of histamine h4 antagonist for the treatment of post-operative adhesions |
| 03/09/2011 | EP2291191A1 Methods for preventing and treating neurodegenerative diseases |
| 03/09/2011 | EP2291183A2 Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 03/09/2011 | EP2178512B1 Tableted compositions containing atazanavir |
| 03/09/2011 | CN101983723A Slow-release medicine carrier |
| 03/09/2011 | CN101297969B Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications |
| 03/08/2011 | US7902366 NK1 antagonists |
| 03/08/2011 | US7902250 Compositions based on aminoacids, suitable for the treatment of heart failure |
| 03/08/2011 | US7902172 Method of promoting bone growth with hyaluronic acid and growth factors |
| 03/08/2011 | US7902170 Influenza virus binding, sialylated oligosaccharide substance and use thereof |
| 03/08/2011 | US7902161 Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell |
| 03/08/2011 | US7902149 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| 03/08/2011 | US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 03/08/2011 | US7901879 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 03/08/2011 | US7901874 Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901709 Active agent, a gel-phase lipid bilayer membrane of a phospholipid and a surface active agent contained in the bilayer membrane; increasing the percentage of active agent released at the phase transition temperature of the lipid bilayer |
| 03/08/2011 | US7901694 Method and apparatus for determining anticoagulant therapy factors |
| 03/08/2011 | US7901687 Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections |
| 03/08/2011 | US7901683 Methods of inhibiting amyloid toxicity |
| 03/08/2011 | US7901678 Medicinal compositions containing Fc receptor γ chain activator |
| 03/08/2011 | US7901674 Aldehyde-fixed platelets with internalized paramagnetic or magnetic nanoparticles |
| 03/08/2011 | US7901672 Methods of making enhanced, autologous fat grafts |
| 03/08/2011 | CA2567807C Activated foam |
| 03/08/2011 | CA2510181C Administration of capsaicinoids |
| 03/08/2011 | CA2486915C Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | CA2468415C Non-human animal model of systemic lupus erythematosus |
| 03/08/2011 | CA2463987C Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| 03/08/2011 | CA2440355C Fibrate-statin combinations with reduced fed-fasted effects |
| 03/08/2011 | CA2434272C Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 03/08/2011 | CA2422531C Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/08/2011 | CA2357881C Polyfluoro copolymer coatings for implantable medical devices |
| 03/08/2011 | CA2329054C A novel polypeptide hormone phosphatonin |
| 03/08/2011 | CA2311734C Flash-melt oral dosage formulation |
| 03/03/2011 | WO2011025368A1 Method of treating frailty |
| 03/03/2011 | WO2011024822A1 Diagnosis marker, diagnosis method and therapeutic agent for amyotrophic lateral sclerosis, and animal model and cell model developing amyotrophic lateral sclerosis |
| 03/03/2011 | WO2011024433A1 Lung and esophageal cancer related gene adamts18 |
| 03/03/2011 | WO2011024154A1 Use of irbesartan for the preparation of a medicament for the prevention of hospitalization for heart failure. |
| 03/03/2011 | WO2010146348A3 Crystalline form of pemirolast |
| 03/03/2011 | WO2010145644A3 Composition for transporting orotic acid across the blood-brain barrier |
| 03/03/2011 | WO2010125408A3 Prostata-norm rectal suppositories for the treatment of prostatitis |
| 03/03/2011 | US20110054159 Rna interference mediating small rna molecules |
| 03/03/2011 | US20110054153 Method of purifying apo-2 ligand/trail usin crystallisation the cold |
| 03/03/2011 | US20110053903 Pharmaceutical compositions based on azetidine derivatives |
| 03/03/2011 | US20110053249 Adenoviruses Mutated In The VA Genes For Cancer Treatment |
| 03/03/2011 | US20110053217 Polynucleotides encoding signal peptide-containing molecules |
| 03/03/2011 | US20110052615 Tumour-specific animal proteins |
| 03/03/2011 | US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses |
| 03/03/2011 | US20110052577 Antibodies |
| 03/03/2011 | CA2759815A1 Method of treating frailty |
| 03/02/2011 | EP2290363A1 Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds |
| 03/02/2011 | EP2289941A2 Administration of agents for the treatment of inflammation |
| 03/02/2011 | EP2289940A2 Treatment of metastatic disease |
| 03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
| 03/02/2011 | EP2289848A2 Therapeutic malonic acid/acetic acid C60 tri-adducts of Buckminsterfullerene and methods related to thereto |
| 03/02/2011 | EP2289556A2 Pharmaceutical composition for use in treatment of diabetes |
| 03/02/2011 | EP2289555A1 Method of treating frailty |
| 03/02/2011 | EP2289554A1 Compositions comprising thalidomide and artemisinin for the treatment of cancer |
| 03/02/2011 | EP2289552A1 An immunosuppressive agent plus anti-TCR antibodies for the induction of chimerism in transplantation |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289521A2 Compositions and methods for use in tergeting vascular destruction |
| 03/02/2011 | EP2289520A1 Use of acetylsalicylic acid for the prophylaxis and/or treatment of influenza virus infection. |
| 03/02/2011 | EP2289519A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 03/02/2011 | EP2289513A2 Method for decreasing the blood glucose level in mammals |
| 03/02/2011 | EP2289512A1 Pharmaceutical foam |
| 03/02/2011 | EP2289508A1 Combined treatment for lung cancer |
| 03/02/2011 | EP2289506A2 Medicament comprising a C11-C21 alkanoic, alkenoic or alkynoic acid ester and a catechin |
| 03/02/2011 | EP2289504A2 SIRT1 modulators for manipulating cell/organism lifespan/stress response |
| 03/02/2011 | EP2289503A2 Treating muscle wasting with selective androgen receptor modulators |
| 03/02/2011 | EP2289502A1 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 03/02/2011 | EP2289501A1 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 03/02/2011 | EP2288385A2 Combination therapy for glaucoma |